Silexion Therapeutics Corp — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Ilan Hadar (CEO) and Mirit Horenshtein-Hadar (CFO) issued Sarbanes-Oxley Section 302 and 906 certifications on August 14, 2026 for the Q2 2026 10-Q (quarter ended June 30, 2026). Both officers certified that the filing complies with SEC requirements, financial statements fairly present the company's condition and results, and internal controls over financial reporting are in place. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Routine SOX compliance certifications; standard periodic disclosure with no operational, financial, or control changes disclosed.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.